1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
Lysine Specific Demethylase 1 (LSD-1) Inhibitors - Pipeline Insight, 2021

Lysine Specific Demethylase 1 (LSD-1) Inhibitors - Pipeline Insight, 2021

  • July 2021
  • 111 pages
  • ID: 6124425
  • Format: PDF
  • Delve Insight

Summary

Table of Contents

“Lysine Specific Demethylase 1 (LSD-1) Inhibitors - Pipeline Insight, 2021,” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Lysine Specific Demethylase 1 (LSD-1) Inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
• Global coverage

Lysine Specific Demethylase 1 (LSD-1) Inhibitors Understanding

Lysine Specific Demethylase 1 (LSD-1) Inhibitors: Overview
Lysine specific demethylase 1 (LSD1, also known as KDM1A (lysine-specific demethylase 1A) or AOF2 (flavin-containing amine oxidase domain-containing protein 2), is an 852 amino acid, 110?kDa, flavin-dependent monoamine oxidase (MAO) protein. LSD1 has three structural domains that regulate its enzymatic activity and binding to several proteins. LSD1 contain a FAD-binding motif (FAD), the SWI3/Rac8/Moira (SWIRM) domain and a catalytic AOD domain.
Function - LSD1 is a central regulator of multiple relevant processes of cellular life, important either for general homeostasis or (if deregulated) tumor progression. LSD1 plays role in: Stem cell renewal, Cell proliferation and differentiation, Tumor progression, and Epithelial-mesenchymal transition. Its function in the nervous system has been recently expanded with the discovery of a new neuron-specific alternative splicing variant named neuroLSD1.
Lysine Specific Demethylase 1 (LSD-1) Inhibitors - Several LSD1 inhibitors including natural products, peptides, and synthetic compounds are currently undergoing clinical assessment for anticancer efficacy, especially in small lung cancer cells and acute myeloid leukemia. Pharmacological inhibition of LSD1 for cancer therapy can be into five subcategories: MAO inactivators and their derivatives, Natural products, Peptide inhibitors, Polyamine-based inhibitors, and Metal-based inhibitors.

Lysine Specific Demethylase 1 (LSD-1) Inhibitors Emerging Drugs Chapters
This segment of the Lysine Specific Demethylase 1 (LSD-1) Inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Lysine Specific Demethylase 1 (LSD-1) Inhibitors Emerging Drugs
• IMG-7289: Imago BioSciences
IMG-7289 (Bomedemstat) is an orally available small molecule, discovered and developed by Imago BioSciences that inhibits lysine-specific demethylase 1 (LSD1 or KDM1A), an enzyme shown to be vital in cancer stem/progenitor cells, particularly neoplastic bone marrow cells. In non-clinical studies, bomedemstat demonstrated robust in vivo anti-tumor efficacy across a range of myeloid malignancies as a single agent and in combination with other therapeutic agents. The drug is being evaluated in Phase II clinical trial to treat patients with Essential thrombocythaemia, Myelofibrosis, and Polycythaemia Vera. In April 2021, the US Food and Drug Administration (FDA) has granted Fast Track designation for the development of IMG-7289 (bomedemstat) for the treatment of Essential Thrombocythemia. The drug has also been granted orphan drug designation by US FDA.
• Iadademstat: Oryzon Genomics
Iadademstat (ORY-1001) is a small oral molecule, which acts as a highly selective inhibitor of the epigenetic enzyme LSD1 and has a powerful differentiating effect in hematologic cancers. Beyond hematological cancers, the inhibition of LSD1 has been proposed as a valid therapeutic approach in some solid tumors such as small cell lung cancer (SCLC), neuroendocrine tumors, medulloblastoma and others. Iadademstat has been tested in four clinical trials (two in monotherapy in SCLC and AML, and two in combination, in SCLC and AML) in more than 100 patients.
• INCB059872: Incyte Corporation
INCB059872 is an orally available inhibitor of lysine-specific demethylase 1 (LSD1; lysine-specific histone demethylase 1A; KDM1A), with potential antineoplastic activity. Upon administration, INCB059872 binds to and inhibits LSD1, a demethylase that suppresses the expression of target genes by converting the di- and mono-methylated forms of lysine at position 4 of histone H3 (H3K4) to mono- and unmethylated H3K4, respectively, through amine oxidation. LSD1 inhibition enhances H3K4 methylation and increases the expression of tumor-suppressor genes. A Phase I/II clinical trial is investigating INCN059872 to treat patients with Solid Tumors and Hematologic Malignancy.
• TAS1440: Astex Pharmaceuticals
TAS1440 is a Lysine-Specific Histone Demethylase 1 inhibitor (LSD1 [also named KDM1A]). LSD1 is an epigenetic regulator. It is aberrantly expressed in many cancers, including AML, where it impedes cellular differentiation which may contribute to leukemia development, cancer cell proliferation, cell metastasis, and invasiveness, and is associated with inferior prognosis. TAS1440 is being evaluated in a first-in-human Phase I clinical study in patients with relapsed/refractory AML.
• RASP-201: Rasna Therapeutics
RASP-201 is a novel, orally dosed, selective reversible inhibitor of lysine specific demethylase, or LSD1, a pathway that blocks differentiation and confers a poor prognosis to AML. RASP-201 when dosed orally shows in vivo therapeutic utility in murine (mouse) models of AML.
Further product details are provided in the report……..

Lysine Specific Demethylase 1 (LSD-1) Inhibitors: Therapeutic Assessment
This segment of the report provides insights about the different Lysine Specific Demethylase 1 (LSD-1) Inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
• Major Players working on Lysine Specific Demethylase 1 (LSD-1) Inhibitors
There are approx. 15+ key companies which are developing the Lysine Specific Demethylase 1 (LSD-1) Inhibitors. The companies which have their Lysine Specific Demethylase 1 (LSD-1) Inhibitors drug candidates in the most advanced stage, i.e. phase II include, Imago BioSciences.
• Phases
This report covers around 15+ products under different phases of clinical development like
• Late-stage products (Phase III and
• Mid-stage products (Phase II and
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration
Lysine Specific Demethylase 1 (LSD-1) Inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Intramuscular
• Oral
• Parenteral
• Subcutaneous
• Topical.
• Molecule Type

Products have been categorized under various Molecule types such as
• Small molecule
• Stem cell therapy
• Peptide
• Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Lysine Specific Demethylase 1 (LSD-1) Inhibitors: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Lysine Specific Demethylase 1 (LSD-1) Inhibitors therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Lysine Specific Demethylase 1 (LSD-1) Inhibitors drugs.

Report Highlights
• The companies and academics are working to assess challenges and seek opportunities that could influence Lysine Specific Demethylase 1 (LSD-1) Inhibitors R&D. The therapies under development are focused on novel approaches for Lysine Specific Demethylase 1 (LSD-1) Inhibitors.

Lysine Specific Demethylase 1 (LSD-1) Inhibitors Report Insights
• Lysine Specific Demethylase 1 (LSD-1) Inhibitors Pipeline Analysis

• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Lysine Specific Demethylase 1 (LSD-1) Inhibitors Report Assessment
• Pipeline Product Profiles

• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:
• How many companies are developing Lysine Specific Demethylase 1 (LSD-1) Inhibitors drugs?
• How many Lysine Specific Demethylase 1 (LSD-1) Inhibitors drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for Lysine Specific Demethylase 1 (LSD-1) Inhibitors?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Lysine Specific Demethylase 1 (LSD-1) Inhibitors therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Lysine Specific Demethylase 1 (LSD-1) Inhibitors and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players
• Imago BioSciences
• Oryzon Genomics
• Celgene
• 4SC
• ExCellThera
• Incyte Corporation
• Salarius Pharmaceuticals
• Astex Pharmaceuticals
• CSPC ZhongQi Pharmaceutical
• Takeda
• Rasna Therapeutics
• Hanmi Pharmaceutical
• Constellation Therapeutics
• Salarius Pharmaceuticals

Key Products
• IMG-7289
• Ladademstat
• Vafidemstat
• CC-90011
• Domatinostat
• UM171
• INCB059872
• Seclidemstat
• TAS1440
• SYHA1807
• TAK-418
• HM97211
• CPI-482
• SP2509

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

ReportLinker may already be registered as a supplier with your company. If you want to Order by PO, check with us first and we'll let you know if we are a registered supplier and what the vendor number is. Otherwise, we'll provide you with the necessary information to register ReportLinker as a vendor.

Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at [email protected] to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - [email protected] or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.

ref:plp2021

Reportlinker.com © Copyright 2021. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on